RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Clinical trials for RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 3

Scientists test powerful new Immune-Boosting cocktail against tough ovarian cancers

Disease control Recruiting now

This study is testing whether adding a new immune-stimulating drug (CDX-1140) to two existing cancer drugs works better for women whose ovarian cancer has returned. The goal is to see if this three-drug combination can shrink tumors more effectively, help patients live longer, an…

Matched conditions: RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control

Last updated Apr 01, 2026 14:43 UTC

RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Get alerted when new RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear

Scientists test powerful new Immune-Boosting cocktail against tough ovarian cancers